AMYPAD announces end of recruitment in the Prognostic and Natural History Study


On 11 May, the members of the Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) project announced the completion of the enrolment of research participants in its Prognostic and Natural History Study (PNHS). The PNHS study is an open-label, prospective and multi-centre cohort study aiming to understand the role of amyloid PET imaging in the earliest stages of Alzheimer’s disease (AD). The first participant was recruited in Amsterdam, The Netherlands, in October 2018. The study has been established to collect amyloid PET scans in a large-scale population in the early stages of AD. The study recruited participants from various European parent cohorts of similar characteristics. The main and original parent cohort was the European Prevention of Alzheimer’s Dementia (EPAD) due to the inherent collaborative framework between the two projects. In addition to EPAD, there were 9 other Parent Cohorts actively recruiting into AMYPAD. These are: EMIF-AD (60++ and 90+), ALFA+, FACEHBI, FPACK, UCL 2010-412, Microbiota, AMYPAD DPMS (VUMC) and H70. On the 30th of April the recruitment was formally ended and the study succeeded in recruiting 1320 participants. As of 11 May 2022, the number of prospective scans collected within AMYPAD PNHS is 1361 (1144 baseline and 217 follow-up).

The non EPAD Parent Cohorts also shared their historical data and therewith the total numbers of scans in AMYPAD PNHS is ~2600. Of course these are not the final numbers as sites are allowed to continue scanning (and collect additional data if applicable). In May and/or June sites will perform their final scans and the Last Patient Out date is the 30th of June 2022. At this moment, seven sites are finished with the scanning of participants (UEDIN, Tayside, CHUT, Nantes, Paris la Pitié, UZ Leuven and Fundació ACE) and the focus will be on the close out of the sites. The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA. This communication reflects the views of the consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.